EA200400087A1 - Система доставки лекарственного вещества по нулевому порядку, нулевому порядку - двухстадийной, возрастающей или убывающей доставки препарата - Google Patents

Система доставки лекарственного вещества по нулевому порядку, нулевому порядку - двухстадийной, возрастающей или убывающей доставки препарата

Info

Publication number
EA200400087A1
EA200400087A1 EA200400087A EA200400087A EA200400087A1 EA 200400087 A1 EA200400087 A1 EA 200400087A1 EA 200400087 A EA200400087 A EA 200400087A EA 200400087 A EA200400087 A EA 200400087A EA 200400087 A1 EA200400087 A1 EA 200400087A1
Authority
EA
Eurasian Patent Office
Prior art keywords
zero order
core
delivery
growing
stage
Prior art date
Application number
EA200400087A
Other languages
English (en)
Other versions
EA005537B1 (ru
Inventor
Моше Флашнер-Барак
Е. Ицхак Лернер
Веред Розенбергер
Original Assignee
Тева Фармасьютикал Индастриес Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриес Лтд. filed Critical Тева Фармасьютикал Индастриес Лтд.
Publication of EA200400087A1 publication Critical patent/EA200400087A1/ru
Publication of EA005537B1 publication Critical patent/EA005537B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Данное изобретение относится к устройству доставки лекарственного вещества для его контролированного выделения, включающему ядро, которое имеет цилиндрическую пробку, вставленную в это ядро, и оболочку, которая, по меньшей мере частично, окружает ядро. Ядро содержит лекарственное вещество и наполнители. Оболочка, окружающая ядро, по существу, непроницаема для лекарственного вещества. Цилиндрическая пробка, которая вставляется в ядро, может быть пустотелой или сплошной. Устройство доставки лекарственного вещества обеспечивает профили выделения лекарственного вещества по нулевому порядку, а также более сложные профили. Изобретение также относится к способу получения устройства доставки лекарственного вещества.Отчет о международном поиске был опубликован 2003.06.05.
EA200400087A 2001-07-10 2002-07-10 Система доставки лекарственного вещества по нулевому порядку, нулевому порядку - двухстадийной, возрастающей или убывающей доставки препарата EA005537B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30380901P 2001-07-10 2001-07-10
PCT/US2002/021661 WO2003005951A2 (en) 2001-07-10 2002-07-10 Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery

Publications (2)

Publication Number Publication Date
EA200400087A1 true EA200400087A1 (ru) 2004-08-26
EA005537B1 EA005537B1 (ru) 2005-04-28

Family

ID=23173802

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400087A EA005537B1 (ru) 2001-07-10 2002-07-10 Система доставки лекарственного вещества по нулевому порядку, нулевому порядку - двухстадийной, возрастающей или убывающей доставки препарата

Country Status (11)

Country Link
US (1) US7195778B2 (ru)
EP (1) EP1414416A4 (ru)
JP (1) JP4426286B2 (ru)
KR (1) KR100892333B1 (ru)
AU (1) AU2002320360B2 (ru)
CA (1) CA2448558A1 (ru)
EA (1) EA005537B1 (ru)
HU (1) HUP0401079A3 (ru)
IL (1) IL159715A0 (ru)
MX (1) MXPA04000209A (ru)
WO (1) WO2003005951A2 (ru)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
EP2316394B1 (en) 2001-06-12 2016-11-23 The Johns Hopkins University Reservoir device for intraocular drug delivery
US20020192676A1 (en) * 2001-06-18 2002-12-19 Madonna Angelo J. Method for determining if a type of bacteria is present in a mixture
US7083578B2 (en) * 2001-07-12 2006-08-01 Given Imaging Ltd. Device and method for examining a body lumen
US7585283B2 (en) * 2001-07-12 2009-09-08 Given Imaging Ltd. Device and method for examining a body lumen
AU2008202321B2 (en) * 2001-07-12 2009-11-19 Given Imaging Ltd Device and method for controlled release of a substance
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) * 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
AU2003228505B2 (en) * 2002-04-12 2009-01-08 Colorado School Of Mines Method for detecting low concentrations of a target bacterium that uses phages to infect target bacterial cells
CA2543353C (en) * 2003-09-19 2012-05-15 Sun Pharmaceutical Industries Limited Oral drug delivery system
US10213387B2 (en) * 2003-09-19 2019-02-26 Sun Pharma Advanced Research Company Ltd. Oral drug delivery system
US10226428B2 (en) * 2003-09-19 2019-03-12 Sun Pharma Advanced Research Company Ltd. Oral drug delivery system
US20070259033A1 (en) * 2003-09-26 2007-11-08 Evangeline Cruz Controlled release formulations exhibiting an ascending rate of release
NZ586198A (en) * 2003-09-26 2011-12-22 Alza Corp Oros push-stick sustained release dosage forms for controlled delivery of active agents
EP1708684A2 (en) * 2003-09-26 2006-10-11 Alza Corporation Drug coating providing high drug loading and methods for providing the same
KR20120106757A (ko) * 2003-09-26 2012-09-26 알자 코포레이션 오피오이드 및 비오피오이드 진통제의 제어 방출 제제
NZ546662A (en) * 2003-10-20 2009-03-31 Teva Pharma Composition and dosage form for sustained effect of levodopa
WO2005046648A1 (en) * 2003-11-12 2005-05-26 Glenmark Pharmaceuticals Ltd. Extended release pharmaceutical dosage forms comprising alpha-2 agonist tizanidine
WO2005056708A2 (en) * 2003-12-09 2005-06-23 Spherics, Inc. Bioadhesive polymers with catechol functionality
PE20060003A1 (es) * 2004-03-12 2006-03-01 Smithkline Beecham Plc Formulacion farmaceutica polimerica para moldear por inyeccion
CN1988884B (zh) * 2004-06-10 2013-01-02 格拉特气体技术公司 控制释放基质的药物剂型组成
US20080311191A1 (en) * 2004-08-27 2008-12-18 Avinash Nangia Multi-Layer Tablets and Bioadhesive Dosage Forms
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
WO2006099618A1 (en) * 2005-03-16 2006-09-21 Dr. Reddy's Laboratories Ltd. Delivery system for multiple drugs
US8092990B2 (en) * 2005-03-31 2012-01-10 Colorado School Of Mines Apparatus and method for detecting microscopic organisms using bacteriophage
KR20080028480A (ko) * 2005-08-01 2008-03-31 테바 파마슈티컬 인더스트리즈 리미티드 티자니딘 조성물 및 이 조성물을 사용하는 치료 방법
US20070212397A1 (en) * 2005-09-15 2007-09-13 Roth Daniel B Pharmaceutical delivery device and method for providing ocular treatment
US10208158B2 (en) 2006-07-10 2019-02-19 Medipacs, Inc. Super elastic epoxy hydrogel
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP2068844A4 (en) * 2006-09-04 2013-01-23 Panacea Biotec Ltd PROGRAMMABLE RELEASE TECHNIQUE BY FLOATING SYSTEM
EP1973528B1 (en) 2006-11-17 2012-11-07 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
WO2008105920A1 (en) * 2007-02-28 2008-09-04 Collegium Pharmaceutical, Inc. Antihistamine combination
WO2009073734A2 (en) 2007-12-03 2009-06-11 Medipacs, Inc. Fluid metering device
US8697434B2 (en) * 2008-01-11 2014-04-15 Colorado School Of Mines Detection of phage amplification by SERS nanoparticles
KR20100136967A (ko) * 2008-02-15 2010-12-29 썬 파마 어드밴스트 리서치 컴패니 리미티드 파열 효과가 감소된 방출 제어 경구 정제
US9441204B2 (en) * 2008-04-03 2016-09-13 Colorado School Of Mines Compositions and methods for detecting Yersinia pestis bacteria
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
US20090312627A1 (en) * 2008-06-16 2009-12-17 Matott Laura A Radio-labeled ingestible capsule
WO2010029095A2 (en) * 2008-09-10 2010-03-18 Sandoz Ag Capsule with soluble blocking element
US20100151020A1 (en) * 2008-12-16 2010-06-17 Vered Rosenberger Drug delivery system for zero order, zero order biphasic, ascending or descending drug delivery of methylphenidate
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CN104887389B (zh) 2009-01-29 2017-06-23 弗赛特影像4股份有限公司 后段给药
WO2011032011A1 (en) 2009-09-10 2011-03-17 Medipacs, Inc. Low profile actuator and improved method of caregiver controlled administration of therapeutics
CN106913902A (zh) 2009-11-09 2017-07-04 聚光灯技术合伙有限责任公司 多糖基水凝胶
CN107033368A (zh) 2009-11-09 2017-08-11 聚光灯技术合伙有限责任公司 碎裂水凝胶
US8945010B2 (en) 2009-12-23 2015-02-03 Covidien Lp Method of evaluating constipation using an ingestible capsule
EP3536333B1 (en) 2010-01-04 2022-08-03 Mapi Pharma Limited Depot system comprising glatiramer acetate
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
US9500186B2 (en) 2010-02-01 2016-11-22 Medipacs, Inc. High surface area polymer actuator with gas mitigating components
SI2600930T1 (sl) 2010-08-05 2021-08-31 Forsight Vision4, Inc. Injekcijska naprava za dajanje zdravila
AU2011285548B2 (en) 2010-08-05 2014-02-06 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
HUE057267T2 (hu) 2010-08-05 2022-05-28 Forsight Vision4 Inc Berendezés szem kezelésére
US8668675B2 (en) 2010-11-03 2014-03-11 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
WO2012080833A2 (en) 2010-12-13 2012-06-21 Purdue Pharma L.P. Controlled release dosage forms
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
DK2688557T3 (da) 2011-03-23 2017-11-27 Ironshore Pharmaceuticals & Dev Inc Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
EP2726016B1 (en) 2011-06-28 2023-07-19 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
US9883968B2 (en) 2011-09-16 2018-02-06 Forsight Vision4, Inc. Fluid exchange apparatus and methods
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
CN104302689A (zh) 2012-03-14 2015-01-21 麦德医像公司 含有过量活性分子的智能聚合物材料
JP6289367B2 (ja) 2012-06-05 2018-03-07 武田薬品工業株式会社 有核錠
US20160193276A1 (en) * 2012-12-21 2016-07-07 Teva Pharmaceutical Industries, Ltd. Transmucosal delivery of glatiramer acetate
EP2943186A1 (en) 2013-01-09 2015-11-18 Edgemont Pharmaceuticals LLC Controlled release formulations of lorazepam
US8999393B1 (en) 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
EP4302736A3 (en) 2013-03-28 2024-04-03 ForSight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
LT3069733T (lt) * 2013-11-13 2022-11-25 National Defense Education And Research Foundation Nauja acetaminofeno junginio sudėtis be šalutinio poveikio kepenims
KR102416726B1 (ko) 2014-07-15 2022-07-05 포사이트 비젼4, 인크. 안구 이식물 전달 디바이스 및 방법
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
WO2016022750A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
AU2016355345A1 (en) 2015-11-20 2018-05-31 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
CN109195556B (zh) 2016-04-05 2021-03-26 弗赛特影像4股份有限公司 可植入眼睛药物递送装置
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
WO2019103906A1 (en) 2017-11-21 2019-05-31 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
JP6858729B2 (ja) * 2018-05-25 2021-04-14 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3977404A (en) * 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US6200600B1 (en) * 1989-02-16 2001-03-13 Btg International Limited Controlled delay release device
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag, Basel Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
GB9326267D0 (en) * 1993-12-23 1994-02-23 Scherer Corp R P Expulsion of material
WO1998023263A1 (en) 1996-11-25 1998-06-04 Alza Corporation Ascending-dose dosage form
AU736912B2 (en) * 1997-02-20 2001-08-02 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
AU2546399A (en) * 1998-02-10 1999-08-30 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
EP1095650A1 (en) * 1999-10-29 2001-05-02 Universiteit Leiden Double phase time-controlled release system
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof

Also Published As

Publication number Publication date
HUP0401079A2 (hu) 2004-08-30
JP2005502625A (ja) 2005-01-27
KR20040027874A (ko) 2004-04-01
CA2448558A1 (en) 2003-01-23
US20030143257A1 (en) 2003-07-31
WO2003005951A3 (en) 2003-06-05
WO2003005951A2 (en) 2003-01-23
EP1414416A2 (en) 2004-05-06
KR100892333B1 (ko) 2009-04-08
JP4426286B2 (ja) 2010-03-03
EP1414416A4 (en) 2007-06-27
MXPA04000209A (es) 2005-03-07
HUP0401079A3 (en) 2008-04-28
AU2002320360B2 (en) 2005-05-26
IL159715A0 (en) 2004-06-20
US7195778B2 (en) 2007-03-27
EA005537B1 (ru) 2005-04-28

Similar Documents

Publication Publication Date Title
EA200400087A1 (ru) Система доставки лекарственного вещества по нулевому порядку, нулевому порядку - двухстадийной, возрастающей или убывающей доставки препарата
ES2172239T3 (es) Sistema osmotico de liberacion de farmacos.
DK1117383T3 (da) Doseringsformer omfattende terapeutisk formulering
EP2269574A3 (en) Implants for administering substances and methods of producing implants
NO20014859L (no) Raskt dispergerbare doseringsformer inneholdende fiskegelatin
EA200400862A1 (ru) Твёрдая лекарственная форма, содержащая сердцевинную таблетку с активным фармацевтическим ингредиентом, покрытую кольцеобразной оболочкой из спрессованного порошкообразного или гранулированного материала, способ приготовления такой лекарственной формы и устройство для её приготовления
FR2627696B1 (fr) Nouvelle forme galenique du fenofibrate
DE69925936D1 (de) Vorrichtung zur lokalen verabreichung einer arznei in einer körperhöhle
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
DE69833375D1 (de) Implantate zur gesteuerten freisetzung von pharmazeutischen wirkstoffen und verfahren zur herstellung
ATE198152T1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
ATA91797A (de) Eine das vwf-propeptid enthaltende pharmazeutische präparation
PT998287E (pt) Utilizacao de levobupivacaina
ATE327737T1 (de) Verfahren zur herstellung von arzneistoffgranulatkörnern, die arzneistoffgranulatkörner sowie diese enthaltende pharmazeutische zubereitungen
YU3101A (sh) Farmaceutska formulacija suspenzije koja obuhvata amoksicilin, klavulonsku kiselinu i celulozu
ATE230979T1 (de) Verfahren zur herstellung neuer fenofibrathaltiger arzneiformulierungen, dadurch hergestellte arzneiformulierungen und ihre verwendung
FI972054A (fi) Immunogeenisiä koostumuksia
IS1664B (is) Ný aðferð við að framleiða útskipt 4-fenýl-4-píperídínkarboxamíð sem hefur bæði staðbundin deyfandiog kvalastillandi áhrif
MXPA05013270A (es) Forma de administracion transmucosal con irritacion mucosal reducida. reducida.
GR20010100377A (el) Φαρμακευτικη συνθεση περιεχουσα σιταλοπραμη
TR200402230T4 (tr) O-ikameli 6-metil-tramadol-türevleri
SE9904121D0 (sv) Hydrophobe biomolecular structure
BR9912533A (pt) Composição farmacêutica tendo sabor melhorado
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
EP1172097A4 (en) PROCESS FOR THE PRODUCTION OF A DRUG COMPOSITION CONTAINING A BASIC HYDROPHOBIC DRUG COMPOUND

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU